Rhythm Pharmaceuticals (RYTM) Other Accumulated Expenses (2016 - 2025)

Rhythm Pharmaceuticals (RYTM) has 10 years of Other Accumulated Expenses data on file, last reported at $3.4 million in Q3 2025.

• On a quarterly basis, Other Accumulated Expenses fell 90.73% year-over-year to $3.4 million in Q3 2025; TTM through Sep 2025 was $3.4 million, a 90.73% decrease from a year earlier, with the FY2024 full-year figure at $37.7 million, up 596.93% from the prior year.
• Other Accumulated Expenses for Q3 2025 stood at $3.4 million, down from $4.4 million in the prior quarter.
• Over the last five years, Other Accumulated Expenses for RYTM reached as high as $37.7 million in Q4 2024 and fell as low as $229000.0 in Q1 2021.
• Historically, Other Accumulated Expenses has averaged $6.8 million across 5 years, with a median of $3.4 million in 2025.
• Across the five-year window, Other Accumulated Expenses surged 876.15% in 2024 and slumped 90.73% in 2025, its largest moves.
• Year by year, Other Accumulated Expenses stood at $800000.0 in 2021, then jumped by 202.38% to $2.4 million in 2022, then jumped by 123.65% to $5.4 million in 2023, then surged by 596.93% to $37.7 million in 2024, then plunged by 90.99% to $3.4 million in 2025.
• Per Business Quant data, the three most recent Other Accumulated Expenses figures were $3.4 million in Q3 2025, $4.4 million in Q2 2025, and $5.8 million in Q1 2025.